Document is current

Documents that mention this clinical trial

252 Novel DNAM-1 axis member, PVRIG, is potentially a dominant checkpoint involved in stem-like memory T cells – dendritic cell interaction
https://doi.org/10.1136/jitc-2021-sitc2021.252

640 The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer
https://doi.org/10.1136/jitc-2023-sitc2023.0640

29 Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701+nivolumab+/-BMS-986207 in patients with platinum resistant ovarian cancer
https://doi.org/10.1136/jitc-2023-sitc2023.0029

478 COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839)
https://doi.org/10.1136/jitc-2021-sitc2021.478

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1

390 COM701 (a novel immune checkpoint inhibitor) in patients with advanced solid tumors
https://doi.org/10.1136/ijgc-2019-igcs.390

504 PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion
https://doi.org/10.1136/jitc-2022-sitc2022.0504

659 COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases
https://doi.org/10.1136/jitc-2022-sitc2022.0659

TIGIT in cancer immunotherapy
https://doi.org/10.1136/jitc-2020-000957